262 related articles for article (PubMed ID: 35204500)
1. Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine.
Sun KM; Wong YH; Cheung KC; Yuen CM; Chan YT; Lai WJ; Chao CD; Fan WK; Chow YK; Law MF; Tam HT
Diagnostics (Basel); 2022 Feb; 12(2):. PubMed ID: 35204500
[TBL] [Abstract][Full Text] [Related]
2. Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type.
Lin N; Ku W; Song Y; Zhu J; Lu Z
Oncologist; 2019 Sep; 24(9):e905-e913. PubMed ID: 30940744
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
4. Advances in multiple omics of natural-killer/T cell lymphoma.
Xiong J; Zhao WL
J Hematol Oncol; 2018 Dec; 11(1):134. PubMed ID: 30514323
[TBL] [Abstract][Full Text] [Related]
5. Contribution of the Epstein-Barr virus to the oncogenesis of mature T-cell lymphoproliferative neoplasms.
Barros MHM; Alves PDS
Front Oncol; 2023; 13():1240359. PubMed ID: 37781191
[TBL] [Abstract][Full Text] [Related]
6. What we should know about natural killer/T-cell lymphomas.
Xiong J; Zhao W
Hematol Oncol; 2019 Jun; 37 Suppl 1():75-81. PubMed ID: 31187536
[TBL] [Abstract][Full Text] [Related]
7. Transcriptomic Abnormalities in Epstein Barr Virus Associated T/NK Lymphoproliferative Disorders.
de Mel S; Tan JZ; Jeyasekharan AD; Chng WJ; Ng SB
Front Pediatr; 2018; 6():405. PubMed ID: 30705877
[TBL] [Abstract][Full Text] [Related]
8. Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.
Peng RJ; Han BW; Cai QQ; Zuo XY; Xia T; Chen JR; Feng LN; Lim JQ; Chen SW; Zeng MS; Guo YM; Li B; Xia XJ; Xia Y; Laurensia Y; Chia BKH; Huang HQ; Young KH; Lim ST; Ong CK; Zeng YX; Bei JX
Leukemia; 2019 Jun; 33(6):1451-1462. PubMed ID: 30546078
[TBL] [Abstract][Full Text] [Related]
9. EBV and the Pathogenesis of NK/T Cell Lymphoma.
Montes-Mojarro IA; Fend F; Quintanilla-Martinez L
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808787
[TBL] [Abstract][Full Text] [Related]
10. Analysis of latent T-cell epitopes in Epstein-Barr virus isolated from extranodal nasal-type natural killer/T-cell lymphoma in Taiwanese population.
Chou CC; Tsao CF; Liao CK; You HL; Wang MC; Huang WT
Exp Mol Pathol; 2021 Feb; 118():104577. PubMed ID: 33242451
[TBL] [Abstract][Full Text] [Related]
11. Epstein - Barr virus positive T and NK-cell lymphoproliferations: Morphological features and differential diagnosis.
Montes-Mojarro IA; Kim WY; Fend F; Quintanilla-Martinez L
Semin Diagn Pathol; 2020 Jan; 37(1):32-46. PubMed ID: 31889602
[TBL] [Abstract][Full Text] [Related]
12. Updating targets for natural killer/T-cell lymphoma immunotherapy.
Xue W; Zhang M
Cancer Biol Med; 2021 Feb; 18(1):52-62. PubMed ID: 33628584
[TBL] [Abstract][Full Text] [Related]
13. Mutational Analysis of Extranodal NK/T-Cell Lymphoma Using Targeted Sequencing with a Comprehensive Cancer Panel.
Choi S; Go JH; Kim EK; Lee H; Lee WM; Cho CS; Han K
Genomics Inform; 2016 Sep; 14(3):78-84. PubMed ID: 27729836
[TBL] [Abstract][Full Text] [Related]
14. The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage.
Zeng L; Huang W; Cao Z; Zheng B; Liu X; Guo L; Feng X
Ann Hematol; 2019 Jun; 98(6):1467-1476. PubMed ID: 30895352
[TBL] [Abstract][Full Text] [Related]
15. Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma.
Hu B; Oki Y
Front Oncol; 2018; 8():139. PubMed ID: 29761078
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathogenic pathways in extranodal NK/T cell lymphoma.
de Mel S; Hue SS; Jeyasekharan AD; Chng WJ; Ng SB
J Hematol Oncol; 2019 Apr; 12(1):33. PubMed ID: 30935402
[TBL] [Abstract][Full Text] [Related]
17. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities.
Kim WY; Nam SJ; Kim S; Kim TM; Heo DS; Kim CW; Jeon YK
Leuk Lymphoma; 2015 Jun; 56(6):1778-86. PubMed ID: 25288491
[TBL] [Abstract][Full Text] [Related]
19. Frequent Mutations in Natural Killer/T Cell Lymphoma.
Zhang Y; Li C; Xue W; Zhang M; Li Z
Cell Physiol Biochem; 2018; 49(1):1-16. PubMed ID: 30134235
[TBL] [Abstract][Full Text] [Related]
20. HACE1, a potential tumor suppressor gene on 6q21, is not involved in extranodal natural killer/T-cell lymphoma pathophysiology.
Sako N; Dessirier V; Bagot M; Bensussan A; Schmitt C
Am J Pathol; 2014 Nov; 184(11):2899-907. PubMed ID: 25203537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
